Abstract
Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have